Y-mabs therapeutics, inc. (YMAB)
CashFlow / Yearly
Dec'19Dec'18Dec'17
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-81,028

-43,274

-19,161

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

166

29

-

Stock-based compensation

4,657

1,966

609

Foreign currency transactions

-43

-97

63

Changes in assets and liabilities:
Other current assets

1,158

2,821

482

Other assets

182

187

-

Accounts payable

2,617

1,261

2,385

Accrued liabilities and other

1,388

1,700

842

NET CASH USED IN OPERATING ACTIVITIES

-73,497

-41,229

-15,870

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment

1,965

234

-

NET CASH USED IN INVESTING ACTIVITIES

-1,965

-234

-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock, net of issuance costs

134,704

99,765

89,844

Payment of offering costs for private placement

-

1,002

258

NET CASH PROVIDED BY FINANCING ACTIVITIES

134,704

98,763

89,586

Effect of exchange rates on cash, cash equivalents and restricted cash

23

56

-104

NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

59,265

57,356

73,612

SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES
Property and equipment purchases in accounts payable

49

-

-

Right-of-use assets obtained in exchange for lease obligations

901

-

-

Common stock issuance cost in accounts payable

-

-

1,002

Deferred offering costs included in other assets and accounts payable and accrued liabilities and other

-

-

514